Monoclonal antibodies: Old and new trends in breast cancer imaging and therapeutic approach

Hellenic Journal of Nuclear Medicine

Volumn 8, Issue 2, 2005, Pages 103-108

  Stipsanelli, Ekaterini ^a   Valsamaki, Pipitsa ^a  

^a ALEXANDRA HOSPITAL   (Greece)

Author keywords

Anti CEA antibody; Immunoscintigraphy; Radioimmunotherapy; Trastuzumab; Yttrium 90 BrE 3 Ab

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY B.72.3 IN 111; TRASTUZUMAB; YTTRIUM 90;

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG APPROVAL; DRUG POTENTIATION; DRUG TARGETING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; ISOTOPE LABELING; LIVER DISEASE; LYMPHOSCINTIGRAPHY; MAMMOGRAPHY; MEDICAL RESEARCH; MONITORING; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CLINICAL TRIALS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 24144449899     PISSN: 00258024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabelled antibodies. Semin Nucl Med 1999; 29: 41-48.
2. Khalkhali I, Maublant JC, Goldsmith SJ. Nuclear oncology. Diagnosis and therapy. 1st edn. Philadelphia: Lippincott Williams and Wilkins; 2001.
3. Ell PJ, Gambhir SS. Nuclear medicine in clinical diagnosis and treatment. 3rd edn. Edinburgh: Churchill Livingstone; 2004.
4. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 1975; 256: 295-297.
5. Wahl RL, Parker CW, Philpott GW. Improved radioimaging and tumour localization with monoclonal F(ab')2. J Nucl Med 1983; 24: 316-325.
6. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci 1984; 81: 6851-6855.
7. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522-525.
8. Bruggemann M, Winter G, Waldmann H, et al. The immunogenicity of chimeric antibodies. J Exp Med 1989; 170: 2153-2157.
9. Wahl RL, Barrett J, Geatti O, et al. The intraperitoneal delivery of radio-labelled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother 1988; 26: 187-201.
10. Goodwin DA. Tumour pretargeting: almost the bottom line. J Nucl Med 1995; 36: 876-879.
11. Williams WV, Moss DA, Kieber-Emmons T, et al. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci USA 1989; 5537-5541.
12. Zuckier LS, Rodriguez LD, Scharff MD. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med 1989; 19: 166-186.
13. Sutherland R, Bucheggar F, Schreyer M, et al. Penetration and binding of radiolabelled anti-carcinoembryonic antigen monoclonal antibodies and their antigen-binding fragments in human colon multicellular tumour spheroids. Cancer Res 1987; 47: 1627-1633.
14. James K, Bell GT. Human monoclonal antibody production: current status and future prospects. J Immunol Methods 1987; 100: 5-40.
15. Rombi G, Cossu F, Melis G. MoAb-labelled liposomes in breast cancer cell targeting: therapeutics and diagnostic use of polyspecific artificial carriers. Ann N Y Acad Sci 1993; 698: 429-435.
16. Mackworth-Young CG. The Michael Mason Prize essay: antiphospholipid antibodies and disease. Br J Rheumatol 1995; 34: 1009-1030.
17. Lind P, Smola MG, Lechner P, et al. The immunoscintigraphic use of Tc-99m-labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int J Cancer 1991; 47: 865-869.
18. Goldenberg DM, DeLand F, Kim EE, et al. Use of radiolabelled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384-1388.
19. Goldenberg DM, Kim EE, DeLand FH, et al. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 1980; 40: 2984-2992.
20. Primus FJ, Newell KD, Blue A, et al. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983; 43: 686-692.
21. Steinstrasser A, Oberhausen E. Anti-CEA labelling kit BW 431/26: results of the European multicenter trial. Nuklearmedizin 1995; 34: 232-242.
22. Kairemo KJ. Immunolymphoscintigraphy with Tc-99m-labelled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer. Cancer Res 1990; 50 (3 Suppl): 949s-954s.
23. Nabi HA, Rosner D, Erb D, et al. Evaluation of suspicious mammographic findings with CEA-Scan and correlation with histopathological results (abstr). J Nucl Med 1996; 37 (Suppl): 238P.
24. Haseman MK, Brown DW, Keeling CA, et al. Radioimmunodetection of occult carcinoembryonic antigen-producing cancer. J Nucl Med 1992; 33: 1750-1756.
25. Rosner D, Abdel-Nabi H, Panaro V, et al. Carcinoembryonic antigen immunoscintigraphy may reduce the number of surgical biopsies in women with mammographically abnormal, non-palpable, benign breast disease (abstr). Proc Am Soc Clin Oncol 1996; 15: 102.
26. Sharkey RM, Goldenberg DM, Murthy S, et al. Clinical evaluation of tumour targeting with a high-affinity, anticarcinoembryonic antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993; 71: 2082-2096.
27. 90Y)-chimeric T84.66 (cT84.66) anti-CEA antibody and autologous stem cell support in CEA-producing metastatic breast cancer (abstr). Cancer Biother Radiopharm 1998; 13: 314.
28. Tjandra JJ, Russell IS, Collins JP, et al. Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer. Cancer Res 1989; 49: 1600-1608.
29. Pecking AP, Lokiec FM. Pre-operative immunolymphoscintigraphy with human monoclonal antibody (16.88 lilo) to assess the nodal involvement in breast cancer. In: Cluzan RV, Peckign AP, Loklec FM, eds. Progress in lymphology XIII. Excerpta Medica, Amsterdam: 1992; 307-311.
30. Nabi HA. Antibody imaging in breast cancer. Semin Nucl Med 1997; 27: 30-39.
31. Price MR, Rye PD, Petrakou E, et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumour Biol 1998; 19 (Suppl 1): 1-20.
32. Karsten U, Diotel C, Klich G, et al. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Res 1998; 58: 2541-2549.
33. 2 in the pre-operative detection of clinical and subclinical lymph node metastases in breast cancer patients. Int J Cancer 1988; 3 (Suppl): 89-95.
34. 99mTc SM3 radioimmunoscintigraphy. Acta Oncol 1996; 35: 319-321.
35. McEwan AJB, MacLean GD, Goldberg L, et al. Evaluating radioimmunoscintigraphy in patients with breast cancer (abstr). Eur J Nucl Med 1994; 21: P748
36. 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991; 51: 5461-5466.
37. 89Zr-labelled monoclonal antibodies. J Nucl Med 2003; 44: 1282-1283.
38. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004; 6: 350-359.
39. Baselga J. Clinical trials of single-agent transuzumab (Herceptin). Semin Oncol 2000; 27: 20-26.
40. DeNardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 1997; 17: 1745-1752.
41. DeNardo SJ, Mirick GR, Kroger LA, et al. The biologic window for chimeric L6 radioimmunotherapy. Cancer 1994; 73 (Suppl): 1023-1032.
42. Goldenberg DM. New developments in monoclonal antibodies for cancer detection and therapy. CA Cancer J Clin 1994; 44: 43-64.
43. 131I-labelled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res 1997; 3: 1547-1555.
44. Howell LP, DeNardo SJ, Levy N, et al. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 1995; 10: 126-135.
45. DeNardo SJ, Richman CM, Goldstein DS, et al. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 1997; 17: 1735-1744.
46. Blank EW, Pant KD, Chan CM, et al. A novel anti-breast epithelial mucin MoAb (BrE-3). Cancer 1992; 5: 38-44.
47. Mattes MJ, Major PP, Goldenberg DM, et al. Patterns of antigen distribution in human carcinomas. Cancer Res 1990; 50[Suppl]: 880-884.
48. DeNardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 1997; 38: 1180-1185.
49. Kramer EL, Liebes L, Wasserheit C, et al. Initial clinical evaluation of radiolabelled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 1998; 4: 1679-1688.
50. Cagnoni PJ, Ceriani RL, Cole WC, et al. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer. Cancer Biother Radiopharm 1998; 13: 328.
51. 90Y Mab 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res 1999; 5: 3243-3248.
52. Richman CM, De Nardo SJ. Systemic radiotherapy in metastatic breast cancer using linked monoclonal MUC-1 antibodies. Critical Rev Oncol Hematol 2001; 38: 25-35.